MSB.AX
Price:
$2.81
Market Cap:
$1.98B
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory b...[Read more]
Industry
Biotechnology
IPO Date
2004-12-15
Stock Exchange
ASX
Ticker
MSB.AX
According to Mesoblast Limited’s latest financial reports and current stock price. The company's current PE Ratio is -9.69. This represents a change of 146.69% compared to the average of -3.93 of the last 4 quarters.
The mean historical PE Ratio of Mesoblast Limited over the last ten years is -18.23. The current -9.69 PE Ratio has changed 5.22% with respect to the historical average. Over the past ten years (40 quarters), MSB.AX's PE Ratio was at its highest in in the December 2017 quarter at 10.64. The PE Ratio was at its lowest in in the September 2019 quarter at -33.58.
Average
-18.23
Median
-9.56
Minimum
-98.03
Maximum
-2.83
Discovering the peaks and valleys of Mesoblast Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 700.42%
Maximum Annual PE Ratio = -2.83
Minimum Annual Increase = -89.30%
Minimum Annual PE Ratio = -98.03
Year | PE Ratio | Change |
---|---|---|
2024 | -7.48 | 15.31% |
2023 | -6.49 | 128.81% |
2022 | -2.83 | -67.16% |
2021 | -8.63 | -41.15% |
2020 | -14.67 | 160.56% |
2019 | -5.63 | -64.35% |
2018 | -15.79 | 50.58% |
2017 | -10.49 | -89.30% |
2016 | -98.03 | 700.42% |
2015 | -12.25 | -53.44% |
The current PE Ratio of Mesoblast Limited (MSB.AX) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-5.60
5-year avg
-8.02
10-year avg
-18.23
Mesoblast Limited’s PE Ratio is less than Nanosonics Limited (72.64), less than Appen Limited (-4.32), less than PolyNovo Limited (272.89), less than Webjet Limited (27.72), less than ResMed Inc. (30.74),
Company | PE Ratio | Market cap |
---|---|---|
72.64 | $944.03M | |
-4.32 | $724.84M | |
272.89 | $1.44B | |
27.72 | $1.73B | |
30.74 | $55.43B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mesoblast Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Mesoblast Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Mesoblast Limited's PE Ratio?
How is the PE Ratio calculated for Mesoblast Limited (MSB.AX)?
What is the highest PE Ratio for Mesoblast Limited (MSB.AX)?
What is the 3-year average PE Ratio for Mesoblast Limited (MSB.AX)?
What is the 5-year average PE Ratio for Mesoblast Limited (MSB.AX)?
How does the current PE Ratio for Mesoblast Limited (MSB.AX) compare to its historical average?